Why did the study with children aged 6 to 11 years consist of patients with only severe disease and not moderate-to-severe?

The safety and efficacy of DUPIXENT have been established in pediatric patients 6 to 17 years of age with moderate-to-severe atopic dermatitis.¹

Use of DUPIXENT in this age group is supported by AD-1652, which included 367 children ages 6 to 11 years of age with severe atopic dermatitis. The safety and efficacy were generally consistent between pediatric and adult patients.¹

Use of DUPIXENT is also supported by AD-1434, an open-label extension study that enrolled subjects who completed AD-1526 and AD-1652. AD-1434 included 136 adolescents from AD-1526 and 110 children from AD-1652 with moderate atopic dermatitis at enrollment into the extension study. AD-1434 included 64 adolescents from AD-1526 and 72 children from AD-1652 with severe atopic dermatitis at enrollment.¹